Article

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford Progeria Syndrome

2021-12-19

Abstract excerpt

<h4>ABSTRACT</h4> Clinical trials have demonstrated that lonafarnib, a farnesyltransferase inhibitor, extends lifespan in patients afflicted by Hutchinson-Gilford progeria syndrome, a devastating condition that accelerates many characteristics of aging and results in premature death due to cardiovascular sequelae. The US Food and Drug Administration approved Zokinvy™ (lonafarnib) in November 2020 for treating the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 28413d9a-a20e-5c68-a4db-2e76b00bc092
DOI: 10.1101/2021.12.17.473197

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford Progeria SyndromeDOI 10.1101/2021.12.17.473197Read

Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndromeSemantic proximity Read

Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson-Gilford Progeria SyndromeSemantic proximity Read

Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.Semantic proximity Read

Progress and trends in the development of therapies for Hutchinson–Gilford progeria syndromeSemantic proximity Read

Paradoxical aortic stiffening and subsequent cardiac dysfunction in Hutchinson-Gilford progeria syndrome.Semantic proximity Read

Improved Arterial Stiffness and Bone Mineral Density in Hutchinson–Gilford Progeria Treated with Bone Marrow-Derived Mesenchymal Stem Cells: A Case Study and Literature ReviewSemantic proximity Read

Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.Semantic proximity Read

Intervention for Critical Aortic Stenosis in Hutchinson-Gilford Progeria SyndromeSemantic proximity Read

Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.Semantic proximity Read

Vascular organoid model of Hutchinson-Gilford progeria syndrome uncovers repression of the SRF pathway in premature aging.Semantic proximity Read

Metabolic Dysfunction in Hutchinson–Gilford Progeria SyndromeSemantic proximity Read

Senescence-inhibitory Δ133p53α counteracts accelerated ageing and mortalitySemantic proximity Read